

# Hans H Kreipe

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7519811/publications.pdf>

Version: 2024-02-01

115  
papers

3,719  
citations

172207

29  
h-index

143772

57  
g-index

119  
all docs

119  
docs citations

119  
times ranked

5871  
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group. <i>Journal of the National Cancer Institute</i> , 2021, 113, 808-819.	3.0	319
2	Trastuzumab emtansine (T-DM1) renders HER2 <sup>+</sup> breast cancer highly susceptible to CTLA-4/PD-1 blockade. <i>Science Translational Medicine</i> , 2015, 7, 315ra188.	5.8	261
3	West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment. <i>Journal of Clinical Oncology</i> , 2016, 34, 2341-2349.	0.8	246
4	Inter-laboratory and inter-observer reproducibility of immunohistochemical assessment of the Ki-67 labelling index in a large multi-centre trial. <i>Journal of Pathology</i> , 2002, 198, 292-299.	2.1	183
5	Histone Deacetylases Activate Hepatocyte Growth Factor Signaling by Repressing MicroRNA-449 in Hepatocellular Carcinoma Cells. <i>Gastroenterology</i> , 2012, 143, 811-820.e15.	0.6	178
6	Increased Chimerism of Bronchial and Alveolar Epithelium in Human Lung Allografts Undergoing Chronic Injury. <i>American Journal of Pathology</i> , 2003, 162, 1487-1494.	1.9	176
7	RIPK3 Restricts Myeloid Leukemogenesis by Promoting Cell Death and Differentiation of Leukemia Initiating Cells. <i>Cancer Cell</i> , 2016, 30, 75-91.	7.7	144
8	Predominance of the basal type and HER-2/neu type in brain metastasis from breast cancer. <i>Modern Pathology</i> , 2007, 20, 864-870.	2.9	135
9	Lobular breast cancer: Clinical, molecular and morphological characteristics. <i>Pathology Research and Practice</i> , 2016, 212, 583-597.	1.0	109
10	High frequency of epithelial chimerism in liver transplants demonstrated by microdissection and STR-analysis. <i>Hepatology</i> , 2002, 35, 110-116.	3.6	107
11	Heterogeneous bone-marrow stromal progenitors drive myelofibrosis via a druggable alarmin axis. <i>Cell Stem Cell</i> , 2021, 28, 637-652.e8.	5.2	92
12	Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial. <i>Leukemia</i> , 2018, 32, 1657-1669.	3.3	86
13	Quality assessment of HER2 testing by monitoring of positivity rates. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2011, 459, 283-289.	1.4	69
14	Problems and pitfalls in grading of bone marrow fibrosis, collagen deposition and osteosclerosis – a consensus-based study. <i>Histopathology</i> , 2016, 68, 905-915.	1.6	67
15	Correlation of MRI and CT findings with histopathology in hepatic angiomyolipoma. <i>European Radiology</i> , 2001, 11, 1389-1395.	2.3	62
16	Increased CXCL4 expression in hematopoietic cells links inflammation and progression of bone marrow fibrosis in MPN. <i>Blood</i> , 2020, 136, 2051-2064.	0.6	56
17	Proficiency testing of immunohistochemical biomarker assays in breast cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2008, 453, 537-543.	1.4	53
18	Macrophage density in early surveillance biopsies predicts future renal transplant function. <i>Kidney International</i> , 2017, 92, 479-489.	2.6	53

#	ARTICLE	IF	CITATIONS
19	Standards and Impact of Hematopathology in Myelodysplastic Syndromes (MDS). <i>Oncotarget</i> , 2010, 1, 483-496.	0.8	52
20	Cytogenetic Aberrations in Primary and Recurrent Fibrolamellar Hepatocellular Carcinoma Detected by Comparative Genomic Hybridization. <i>American Journal of Clinical Pathology</i> , 2000, 114, 867-874.	0.4	50
21	Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2- Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 2557-2567.	0.8	49
22	Quantitative Analysis of Promoter Hypermethylation in Laser-Microdissected Archival Specimens. <i>Laboratory Investigation</i> , 2001, 81, 635-637.	1.7	45
23	Routine clinical mutation profiling using next generation sequencing and a customized gene panel improves diagnostic precision in myeloid neoplasms. <i>Oncotarget</i> , 2016, 7, 30084-30093.	0.8	42
24	The region-of-interest size impacts on Ki67 quantification by computer-assisted image analysis in breast cancer. <i>Human Pathology</i> , 2015, 46, 1341-1349.	1.1	41
25	Molecular Analysis of Circulating Cell-Free DNA from Lung Cancer Patients in Routine Laboratory Practice. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 722-732.	1.2	37
26	Amplification of Growth Regulatory Genes in Intraductal Breast Cancer Is Associated with Higher Nuclear Grade but Not with the Progression to Invasiveness. <i>Laboratory Investigation</i> , 2001, 81, 565-571.	1.7	35
27	Molecular Profiling in Lung Biopsies of Human Pulmonary Allografts to Predict Chronic Lung Allograft Dysfunction. <i>American Journal of Pathology</i> , 2015, 185, 3178-3188.	1.9	35
28	Lobular Breast Cancer: Histomorphology and Different Concepts of a Special Spectrum of Tumors. <i>Cancers</i> , 2021, 13, 3695.	1.7	35
29	Differential impact of prognostic parameters in hormone receptor- positive lobular breast cancer. <i>Cancer</i> , 2020, 126, 4847-4858.	2.0	33
30	Breast Cancer Anti-Estrogen Resistance 4 (BCAR4) Drives Proliferation of IPH-926 lobular Carcinoma Cells. <i>PLoS ONE</i> , 2015, 10, e0136845.	1.1	30
31	EGFR T790M mutation testing of non-small cell lung cancer tissue and blood samples artificially spiked with circulating cell-free tumor DNA: results of a round robin trial. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 509-520.	1.4	29
32	Estrogen receptor (ESR1) mutation in bone metastases from breast cancer. <i>Modern Pathology</i> , 2018, 31, 56-61.	2.9	29
33	<i>CDKN2A</i> loss and <i>PIK3CA</i> mutation in myoepithelial-like metaplastic breast cancer. <i>Journal of Pathology</i> , 2018, 245, 373-383.	2.1	28
34	<i>ERBB2</i> mutation frequency in lobular breast cancer with pleomorphic histology or high-risk characteristics by molecular expression profiling. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 175-185.	1.5	27
35	Mutations associated with age-related clonal hematopoiesis in PMF patients with rapid progression to myelofibrosis. <i>Leukemia</i> , 2020, 34, 1364-1372.	3.3	27
36	E-cadherin to P-cadherin switching in lobular breast cancer with tubular elements. <i>Modern Pathology</i> , 2020, 33, 2483-2498.	2.9	26

#	ARTICLE	IF	CITATIONS
37	Cell cycle and no end. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2004, 444, 313-323.	1.4	24
38	Bone marrow infiltration pattern in B-cell chronic lymphocytic leukemia is related to immunoglobulin heavy-chain variable region mutation status and expression of 70-kd Î¶-associated protein (ZAP-70). <i>Human Pathology</i> , 2006, 37, 1153-1161.	1.1	24
39	NGS-based BRCA1/2 mutation testing of high-grade serous ovarian cancer tissue: results and conclusions of the first international round robin trial. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 468, 697-705.	1.4	24
40	Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal. <i>EBioMedicine</i> , 2017, 26, 17-24.	2.7	24
41	Classical Hodgkin lymphoma-type PTLD after solid organ transplantation in children: a report on 17 patients treated according to subsequent GPOH-HD treatment schedules. <i>Leukemia and Lymphoma</i> , 2017, 58, 633-638.	0.6	24
42	Lobular carcinoma in situ and invasive lobular breast cancer are characterized by enhanced expression of transcription factor AP-2Î². <i>Laboratory Investigation</i> , 2018, 98, 117-129.	1.7	24
43	Response-Adapted Sequential Immuno-Chemotherapy of Post-Transplant Lymphoproliferative Disorders in Pediatric Solid Organ Transplant Recipients: Results from the Prospective Ped-PTLD 2005 Trial. <i>Blood</i> , 2014, 124, 4468-4468.	0.6	24
44	A child with Liâ€™Fraumeni syndrome: Modes to inactivate the second allele of <i>TP53</i> in three different malignancies. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1481-1484.	0.8	22
45	Do programmed death 1 (PD-1) and its ligand (PD-L1) play a role in patients with non-clear cell renal cell carcinoma?. <i>Medical Oncology</i> , 2016, 33, 59.	1.2	22
46	Myelofibrosis: molecular and cell biological aspects. <i>Fibrogenesis and Tissue Repair</i> , 2012, 5, S21.	3.4	19
47	Comprehensive mutation profiling and mRNA expression analysis in atypical chronic myeloid leukemia in comparison with chronic myelomonocytic leukemia. <i>Cancer Medicine</i> , 2019, 8, 742-750.	1.3	19
48	Interobserver agreement for the histological diagnosis of invasive lobular breast carcinoma. <i>Journal of Pathology: Clinical Research</i> , 2022, 8, 191-205.	1.3	19
49	Post-transplant lymphoproliferative disorders with naso- and oropharyngeal manifestation. <i>Transplant International</i> , 2015, 28, 1299-1307.	0.8	18
50	Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study. <i>Modern Pathology</i> , 2022, 35, 1362-1369.	2.9	18
51	Prognostic value of cytotoxic T-lymphocytes and CD40 in biopsies with early renal allograft rejection. <i>Transplant International</i> , 2004, 17, 293-300.	0.8	17
52	Aberrant proplatelet formation in chronic myeloproliferative neoplasms. <i>Leukemia Research</i> , 2010, 34, 1424-1429.	0.4	17
53	Progression of myeloproliferative neoplasms to myelofibrosis and acute leukaemia. <i>Journal of Hematopathology</i> , 2011, 4, 61-68.	0.2	17
54	<i>hsa-mir-183</i> is frequently methylated and related to poor survival in human hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2017, 23, 1568.	1.4	17

#	ARTICLE	IF	CITATIONS
55	Transcription factor $\beta$ in development, differentiation and tumorigenesis. International Journal of Cancer, 2021, 149, 1221-1227.	2.3	16
56	Expression of Toll-Like Receptors in Chronic Histiocytic Intervillositis of the Placenta. Fetal and Pediatric Pathology, 2015, 34, 407-412.	0.4	15
57	Telomere dynamics in patients with del (5q) MDS before and under treatment with lenalidomide. Leukemia Research, 2015, 39, 1292-1298.	0.4	15
58	Telomere shortening, TP53 mutations and deletions in chronic lymphocytic leukemia result in increased chromosomal instability and breakpoint clustering in heterochromatic regions. Annals of Hematology, 2017, 96, 1493-1500.	0.8	15
59	Loss of DNA methylation at imprinted loci is a frequent event in hepatocellular carcinoma and identifies patients with shortened survival. Clinical Epigenetics, 2015, 7, 110.	1.8	14
60	Molecular defects in BRAF wild-type ameloblastomas and craniopharyngiomas—differences in mutation profiles in epithelial-derived oropharyngeal neoplasms. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 472, 1055-1059.	1.4	14
61	Activating human epidermal growth factor receptor 2 (HER2) gene mutation in bone metastases from breast cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 473, 577-582.	1.4	14
62	TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer. Cancer Medicine, 2021, 10, 8581-8594.	1.3	14
63	Prognostic factors in the myoepithelial-like spindle cell type of metaplastic breast cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 469, 191-201.	1.4	12
64	EGFR immunohistochemistry as biomarker for antibody-based therapy of squamous NSCLC—Experience from the first ring trial of the German Quality Assurance Initiative for Pathology (QuIP®). Pathology Research and Practice, 2017, 213, 1530-1535.	1.0	12
65	LINE-1 hypomethylation in human hepatocellular carcinomas correlates with shorter overall survival and CIMP phenotype. PLoS ONE, 2019, 14, e0216374.	1.1	12
66	Precise ERBB2 copy number assessment in breast cancer by means of molecular inversion probe array analysis. Oncotarget, 2016, 7, 82733-82740.	0.8	11
67	Reduction of Erythropoiesis in MDS with 5q Deletion Is Associated with Aberrant SPARC and TNF-Alpha Gene Expression and Predicts the Efficacy of Lenalidomide Therapy.. Blood, 2012, 120, 2826-2826.	0.6	11
68	Cytokine Expression Pattern in Bone Marrow Microenvironment after Allogeneic Stem Cell Transplantation in Primary Myelofibrosis. Biology of Blood and Marrow Transplantation, 2016, 22, 644-650.	2.0	10
69	Profile of fibrosis-related gene transcripts and megakaryocytic changes in the bone marrow of myelodysplastic syndromes with fibrosis. Annals of Hematology, 2018, 97, 2099-2106.	0.8	10
70	Complement receptor-associated CD163+/CD18+/CD11c+/CD206-/CD209- expression profile in chronic histiocytic intervillitis of the placenta. Placenta, 2019, 78, 23-28.	0.7	10
71	Correlating 3D morphology with molecular pathology: fibrotic remodelling in human lung biopsies. Thorax, 2015, 70, 1197-1198.	2.7	9
72	A multicenter prospective, randomized, placebo-controlled phase II/III trial for preemptive acute graft-versus-host disease therapy. Leukemia, 2021, 35, 1763-1772.	3.3	9

#	ARTICLE	IF	CITATIONS
73	Routes of Clonal Evolution into Complex Karyotypes in Myelodysplastic Syndrome Patients with 5q Deletion. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3269.	1.8	8
74	Limited Value of KAI1/CD82 Protein Expression as a Prognostic Marker in Human Gastric Cancer. <i>Disease Markers</i> , 2012, 32, 337-342.	0.6	5
75	Chronic progressive pulmonary paracoccidioidomycosis in a female immigrant from Venezuela. <i>Therapeutic Advances in Respiratory Disease</i> , 2019, 13, 175346661989491.	1.0	5
76	Long-Term Cytogenetic Follow-up of MDS Patients with 5q- Treated within the MDS-003 (CC-5013-MDS-003) Study: Evolution to Complex Clones and Progression to AML. <i>Blood</i> , 2008, 112, 1647-1647.	0.6	5
77	Ectopic Expression of the Extracellular Domain of Mpl Is Sufficient to Induce a Hematopoietic Population Crisis. <i>Blood</i> , 2008, 112, 2886-2886.	0.6	4
78	ERBB2 mutation is associated with sustained tumor cell proliferation after short-term preoperative endocrine therapy in early lobular breast cancer. <i>Modern Pathology</i> , 2022, 35, 1804-1811.	2.9	4
79	Detection of chromosomal imbalances in hepatocellular carcinoma. <i>Expert Review of Molecular Diagnostics</i> , 2002, 2, 120-128.	1.5	3
80	Image analysis of immune cell patterns in the human mammary gland during the menstrual cycle refines lymphocytic lobulitis. <i>Breast Cancer Research and Treatment</i> , 2017, 164, 305-315.	1.1	3
81	Variant of classical high grade PTLD: post-transplant EBV-negative T cell lymphoblastic leukaemia after solid organ transplantation. <i>Annals of Hematology</i> , 2017, 96, 1403-1405.	0.8	3
82	Chromosome 2q gain and epigenetic silencing of <sc>GATA3</sc> in microglandular adenosis of the breast. <i>Journal of Pathology: Clinical Research</i> , 2021, 7, 220-232.	1.3	3
83	Abstract PD10-11: Keyriched-1- A prospective, multicenter, open label, neoadjuvant phase ii single arm study with pembrolizumab in combination with dual anti-HER2 blockade with trastuzumab and pertuzumab in early breast cancer patients with molecular HER2-enriched intrinsic subtype. <i>Cancer Research</i> , 2022, 82, PD10-11-PD10-11.	0.4	3
84	Evolution of severe (transfusionâ€dependent) anaemia in myelodysplastic syndromes with 5q deletion is characterized by a macrophageâ€associated failure of the erythropoietic niche. <i>British Journal of Haematology</i> , 2022, , .	1.2	3
85	MicroRNA expression profiles in BCR-ABL-negative primary myelofibrosis with chromosome 7q defects. <i>Journal of Hematopathology</i> , 2015, 8, 203-208.	0.2	2
86	Aberrant expression of caspase 14 in salivary gland carcinomas. <i>Journal of Oral Pathology and Medicine</i> , 2015, 44, 444-448.	1.4	2
87	Molecular profile of inflammatory and megakaryocytic factors in pediatric myelodysplastic syndrome with acute myelofibrosis. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27048.	0.8	2
88	Coincidence of lymphomatoid granulomatosis, chronic myelomonocytic leukemia, and anaplastic T cell lymphoma after methotrexate therapy for rheumatoid arthritis. <i>Annals of Hematology</i> , 2019, 98, 515-517.	0.8	2
89	Lobular neoplasia and invasive lobular breast cancer: Inter-observer agreement for histological grading and subclassification. <i>Pathology Research and Practice</i> , 2019, 215, 152611.	1.0	2
90	Feasibility of Combined Detection of Gene Mutations and Fusion Transcripts in Bone Marrow Trepines from Leukemic Neoplasms. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 591-598.	1.2	2

#	ARTICLE	IF	CITATIONS
91	The Phenotype of Human STK4 Deficiency. <i>Blood</i> , 2011, 118, 692-692.	0.6	2
92	G6PC3 Deficiency Associated with Congenital Neutropenia and Enterocolitis. <i>Blood</i> , 2011, 118, 2170-2170.	0.6	2
93	Transcriptional Landscape of the Microenvironment in Bone Marrow Fibrosis at Single Cell Level. <i>Blood</i> , 2019, 134, 1675-1675.	0.6	2
94	Comparison of clinical diagnoses and autopsy findings in 54 cases with lymphoid neoplasms. <i>Journal of Hematopathology</i> , 2019, 12, 67-74.	0.2	1
95	Genome-wide DNA methylation profiling is able to identify prefibrotic PMF cases at risk for progression to myelofibrosis. <i>Clinical Epigenetics</i> , 2021, 13, 28.	1.8	1
96	Hodgkin's Disease / Hodgkin-PTLD after Solid Organ Transplantation in Children: A Report on 16 Patients Treated According to Subsequent Gpoh-HD Treatment Schedules. <i>Blood</i> , 2014, 124, 1612-1612.	0.6	1
97	The Kinetic Of Bone Marrow Fibrosis Regression Predicts Outcome In Myelofibrosis Patients After Allogeneic SCT. <i>Blood</i> , 2013, 122, 2078-2078.	0.6	1
98	Clinically latent and autopsy-verified inflammatory disorders and malignant tumours in transplant patients. <i>Journal of Clinical Pathology</i> , 2020, , jclinpath-2020-207080.	1.0	1
99	CD20/CD79a/PAX5/CD3-negative post-transplant lymphoma with aberrant actin and desmin co-expression—a potential differential diagnostic pitfall between PTLD and PTSMT. <i>Annals of Hematology</i> , 2022, 101, 881-883.	0.8	1
100	Donor-transmitted extramedullary acute myeloid leukaemia after living donor kidney transplantation. <i>British Journal of Haematology</i> , 2022, , .	1.2	1
101	Cytokeratin RNA amplification as a molecular method for the detection of lymph node metastases in breast cancer patients. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2009, 455, 93-94.	1.4	0
102	Myeloablative Conditioning of Patients with Myelofibrosis with Myeloid Metaplasia Using i.v. Treosulfan and Autologous Peripheral Blood Progenitor Cell Transplantation (PBPC) with High Doses of CD34+ Cells Results in Hematologic Responses - 32 Months Follow-Up of Three Patients and Short-Term Results of a New Study.. <i>Blood</i> , 2005, 106, 5515-5515.	0.6	0
103	Patients with Del(5q) MDS Who Fail to Achieve Erythroid or Cytogenetic Remission After Treatment with Lenalidomide Have An Increased Risk for Clonal Evolution and AML Progression.. <i>Blood</i> , 2009, 114, 3818-3818.	0.6	0
104	Severe Early-Onset Inflammatory Bowel Disease Caused by IL10 Receptor Deficiency Can Be Cured by Allogeneic Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , 2009, 114, 713-713.	0.6	0
105	New G-CSF-Dependent Signaling Pathway and Its Role In Patients with Severe Congenital Neutropenia and Acute Myeloid Leukemia. <i>Blood</i> , 2010, 116, 385-385.	0.6	0
106	Short Telomeres Before Lenalidomide Treatment Predict Leukemic Progression In Patients with Myelodysplastic Syndrome and Deletion 5q. <i>Blood</i> , 2010, 116, 30-30.	0.6	0
107	Prognosis of Low- or Intermediate-1-Risk MDS with Del(5q) Chromosome Abnormality During Lenalidomide Therapy Depends on the Capacity of the Neoplastic Stem Cell to Differentiate Into Maturing Erythroid Committed Stem Cells,. <i>Blood</i> , 2011, 118, 3819-3819.	0.6	0
108	Telomere Shortening and Chromosomal Instability in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2011, 118, 1761-1761.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Treatment of Myelofibrosis Using I.V. Treosulfan and Autologous Peripheral Blood Progenitor Cell Transplantation Is Feasible and Results in Hematologic Responses â€” Long-Term Follow-up and Final Analysis of a One-Armed Clinical Study and of Individual Cases. Blood, 2011, 118, 4514-4514.	0.6	0
110	Routes of Clonal Evolution Into Complex Karyotypes in Myelodysplastic Syndrome Patients with Del(5q). Blood, 2012, 120, 522-522.	0.6	0
111	Pomalidomide in Myelofibrosis with Cytopenia: First Results of the Mpnsg 01â€”09 Study (ClinicalTrials.gov Identifier: NCT00949364).. Blood, 2012, 120, 2840-2840.	0.6	0
112	Telomere Length Of Granulocytes Significantly Increases During The First Six Months Of Lenalidomide Treatment In Patients With Isolated 5q- Syndrome. Blood, 2013, 122, 2781-2781.	0.6	0
113	Pomalidomide In MPNâ€”associated Myelofibrosis With Cytopenia: Results Of The Mpnsg 01-09 Study. Blood, 2013, 122, 2822-2822.	0.6	0
114	Response to Front-Line Imatinib Treatment in Children and Adolescents with CML - Data from a Large Pediatric Cohort. Blood, 2017, 130, 898-898.	0.6	0
115	Abstract P2-13-03: KEYRICHD-1 - A prospective, multicenter, open label, neoadjuvant phase II single arm study with pembrolizumab in combination with dual anti-HER2 blockade with trastuzumab and pertuzumab in early breast cancer patients with molecular HER2-enriched intrinsic subtype. Cancer Research, 2022, 82, P2-13-03-P2-13-03.	0.4	0